Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board's Determination that Activist Group's Nominations Are Invalid
AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
1
2
3
4
5
6
7
8
<<
<
>
>>
Privacy